StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note published on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reaffirmed a buy rating and set a $40.00 price objective on shares of Bio-Path in a report on Thursday, April 18th.

Bio-Path Trading Down 7.3 %

NASDAQ BPTH opened at $2.49 on Wednesday. The company has a fifty day simple moving average of $5.01 and a 200 day simple moving average of $8.42. The company has a market cap of $1.69 million, a P/E ratio of -0.06 and a beta of 0.35. Bio-Path has a 1 year low of $2.46 and a 1 year high of $44.80.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($5.40). During the same quarter in the prior year, the company earned ($10.60) EPS. Equities research analysts forecast that Bio-Path will post -18.71 EPS for the current fiscal year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.